267 related articles for article (PubMed ID: 12437645)
21. Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia.
Privitera E; Rivolta A; Ronchetti D; Mosna G; Giudici G; Biondi A
Br J Haematol; 1996 Mar; 92(3):653-8. PubMed ID: 8616031
[TBL] [Abstract][Full Text] [Related]
22. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Pongers-Willemse MJ; Seriu T; Stolz F; d'Aniello E; Gameiro P; Pisa P; Gonzalez M; Bartram CR; Panzer-Grümayer ER; Biondi A; San Miguel JF; van Dongen JJ
Leukemia; 1999 Jan; 13(1):110-8. PubMed ID: 10049045
[TBL] [Abstract][Full Text] [Related]
23. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia.
Mortuza FY; Papaioannou M; Moreira IM; Coyle LA; Gameiro P; Gandini D; Prentice HG; Goldstone A; Hoffbrand AV; Foroni L
J Clin Oncol; 2002 Feb; 20(4):1094-104. PubMed ID: 11844835
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia.
Goulden NJ; Knechtli CJ; Garland RJ; Langlands K; Hancock JP; Potter MN; Steward CG; Oakhill A
Br J Haematol; 1998 Jan; 100(1):235-44. PubMed ID: 9450818
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease analysis in children with t(12;21)-positive acute lymphoblastic leukemia: comparison of Ig/TCR rearrangements and the genomic fusion gene.
Metzler M; Mann G; Monschein U; Lodzinski M; Gall C; Flohr T; Viehmann S; Langer T; Schrappe M; Gadner H; Haas OA; Panzer-Grümayer ER
Haematologica; 2006 May; 91(5):683-6. PubMed ID: 16627248
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
28. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups.
Scrideli CA; Assumpção JG; Ganazza MA; Araújo M; Toledo SR; Lee ML; Delbuono E; Petrilli AS; Queiróz RP; Biondi A; Viana MB; Yunes JA; Brandalise SR; Tone LG
Haematologica; 2009 Jun; 94(6):781-9. PubMed ID: 19483156
[TBL] [Abstract][Full Text] [Related]
29. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
30. Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.
Katsibardi K; Moschovi MA; Braoudaki M; Papadhimitriou SI; Papathanasiou C; Tzortzatou-Stathopoulou F
Leuk Lymphoma; 2010 May; 51(5):846-52. PubMed ID: 20350276
[TBL] [Abstract][Full Text] [Related]
31. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.
Raff T; Gökbuget N; Lüschen S; Reutzel R; Ritgen M; Irmer S; Böttcher S; Horst HA; Kneba M; Hoelzer D; Brüggemann M;
Blood; 2007 Feb; 109(3):910-5. PubMed ID: 17023577
[TBL] [Abstract][Full Text] [Related]
32. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
Bartram J; Wade R; Vora A; Hancock J; Mitchell C; Kinsey S; Steward C; Moppett J; Goulden N
Arch Dis Child; 2016 May; 101(5):449-54. PubMed ID: 26865705
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Kuang S; Gu L; Dong S; Cao Q; Xu C; Huang W; Su XY; Huang QH; Xie JX; Chen SJ; Chen Z
Cancer Genet Cytogenet; 1996 Jun; 88(2):110-7. PubMed ID: 8640718
[TBL] [Abstract][Full Text] [Related]
34. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.
Zhou J; Goldwasser MA; Li A; Dahlberg SE; Neuberg D; Wang H; Dalton V; McBride KD; Sallan SE; Silverman LB; Gribben JG;
Blood; 2007 Sep; 110(5):1607-11. PubMed ID: 17485550
[TBL] [Abstract][Full Text] [Related]
35. Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.
Cazzaniga G; d'Aniello E; Corral L; Biondi A
Best Pract Res Clin Haematol; 2002 Dec; 15(4):623-38. PubMed ID: 12617867
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.
Thörn I; Forestier E; Botling J; Thuresson B; Wasslavik C; Björklund E; Li A; Lindström-Eriksson E; Malec M; Grönlund E; Torikka K; Heldrup J; Abrahamsson J; Behrendtz M; Söderhäll S; Jacobsson S; Olofsson T; Porwit A; Lönnerholm G; Rosenquist R; Sundström C
Br J Haematol; 2011 Mar; 152(6):743-53. PubMed ID: 21250970
[TBL] [Abstract][Full Text] [Related]
37. Detection of minimal residual disease in peripheral blood prior to clinical relapse of childhood acute lymphoblastic leukaemia using PCR.
Lal A; Kwan E; Haber M; Norris MD; Marshall GM
Mol Cell Probes; 2001 Apr; 15(2):99-103. PubMed ID: 11292328
[TBL] [Abstract][Full Text] [Related]
38. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
de Haas V; Breunis WB; Dee R; Verhagen OJ; Kroes W; van Wering ER; van Dongen JJ; van den Berg H; van der Schoot CE
Br J Haematol; 2002 Jan; 116(1):87-93. PubMed ID: 11841400
[TBL] [Abstract][Full Text] [Related]
39. Low frequency of clonotypic Ig and T-cell receptor gene rearrangements in t(4;11) infant acute lymphoblastic leukaemia and its implication for the detection of minimal residual disease.
Peham M; Panzer S; Fasching K; Haas OA; Fischer S; Marschalek R; Gadner H; Panzer-Grümayer ER
Br J Haematol; 2002 May; 117(2):315-21. PubMed ID: 11972513
[TBL] [Abstract][Full Text] [Related]
40. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome.
Nyvold C; Madsen HO; Ryder LP; Seyfarth J; Svejgaard A; Clausen N; Wesenberg F; Jonsson OG; Forestier E; Schmiegelow K;
Blood; 2002 Feb; 99(4):1253-8. PubMed ID: 11830473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
